ArticleIranian journal of microbiology2022
Antimicrobial effect of silver and gold nanoparticles in combination with linezolid on
Article in Iranian journal of microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Biogenic Silver-Selenium nanocomposite with anticancer activity and potent efficacy against vancomycin-resistant Staphylococcus aureus.PloS one · 2026Article
- The molecular basis of Staphylococcus aureus resistance to linezolid and the role of silver nanoparticles in attenuating linezolid resistance.Molecular biology reports · 2025Article
- Article
- Analysis of molecular epidemiological characteristics and antimicrobial susceptibility of vancomycin-resistant and linezolid-resistant Enterococcus in China.BMC medical genomics · 2024Article
- Nanosilver: An Old Antibacterial Agent with Great Promise in the Fight against Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: In the past few years, application of new antimicrobial e.g. nanoparticles (NPs) to treat infection caused by drug-resistant bacteria has increased. This study aimed to determine antimicrobial property of silver nanoparticles (AgNPs) and gold nanoparticles (AuNPs) in combination with linezolid on Materials and Methods: A total of forty-eight isolates of Results: Twenty-two Conclusion: The antibiofilm activity of AgNPs and AuNPs increased when both agents were used in combination with linezolid in comparison with each agent alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.